Revlimid Reproductive Safety Concerns Led To Broad Risk Management Plan
This article was originally published in The Pink Sheet Daily
Executive Summary
Office of Drug Safety found RevAssist program acceptable for interim use of the myelodysplastic syndromes therapy until "questionable teratogenicity of lanalidomide is fully characterized and resolved."
You may also be interested in...
Celgene’s Revlimid Approved For Second-Line Multiple Myeloma
Firm will begin shipping 15 mg and 25 mg tablets at the end of the first week of July following sNDA approval announced June 29.
Celgene’s Revlimid Approved For Second-Line Multiple Myeloma
Firm will begin shipping 15 mg and 25 mg tablets at the end of the first week of July following sNDA approval announced June 29.
MGI/SuperGen’s Dacogen On Deck For Late May Launch
The myelodysplastic syndromes therapy could post $25 mil. in 2006 sales, MGI said following the May 3 approval.